
Diabetic foot ulcer (DFU) is a leading cause of disability and mortality in patients with diabetes, with recurrence rates exceeding 40
Intervertebral disc degeneration (IDD) is a leading cause of chronic low back pain and disability worldwide, yet disease-modifying therapies remain unavailable. Nucleus pulposus stem cells (NPSCs) maintain disc homeostasis through their quiescent state. However, how mechanical microenvironmental alterations, particularly extracellular matrix (ECM) stiffening, govern NPSC quiescence remains poorly understood. We sought to identify the mechanotransduction pathways linking ECM stiffness to NPSC quiescence regulation and explore their relevance in vivo. Human NP tissue analysis, public scRNA-seq reanalysis, 3D rat NPSC culture and rodent models were combined. NPSCs were cultured in GelMA hydrogels with Soft (4.85 kPa) or Stiff (13.80 kPa) compression modulus. Transcriptomic, pharmacological, calcineurin, NFATC1 knockdown and promoter-reporter assays examined the PIEZO1-Ca²⁺-NFATC1-CXCL1 axis. The CXCR1/2 inhibitor Reparixin was tested in vitro and with GelMA-NPSC delivery in a rat nucleotomy model. Piezo1CKO mice underwent disc puncture to assess the contribution of PIEZO1. scRNA-Seq reanalysis identified an operationally defined NPSC-like population and exploratory evidence of increased cell-cycle engagement during early degeneration, particularly between Pfirrmann grades II and III. Severely degenerated NP tissues exhibited higher compression modulus. In 3D culture, Stiff matrix drove NPSCs out of quiescence with NANOG/SOX2 downregulation, independent of cellular senescence. Bulk RNA-Seq identified Cxcl1 as the most abundant cytokine among the shared inflammatory leading-edge genes. Matrix stiffening increased intracellular Ca²⁺, calcineurin activity and NFATC1 nuclear localization. Tacrolimus reduced calcineurin activity and CXCL1 secretion under Stiff conditions, supporting calcineurin involvement. NFATC1 promoter occupancy, reporter activity and knockdown supported direct regulation of CXCL1 transcription. CXCL1-CXCR1/2 signaling was associated with increased AKT phosphorylation and changes in autophagy-related markers. GsMTx4 or Reparixin restored quiescence-associated markers. In exploratory short-term in vivo analyses, GelMA-NPSC + Reparixin showed greater disc-height preservation and proteoglycan deposition than GelMA-NPSC alone, whereas Piezo1CKO mice showed higher normalized DHI than controls at the matched puncture level in the primary analysis. These findings support a PIEZO1-Ca²⁺-NFATC1-CXCL1 pathway linking ECM stiffness to NPSC quiescence regulation and provide a rationale for further preclinical evaluation of this axis in early IDD.
Wilson disease (WD) results from pathogenic ATP7B variants that impair hepatic copper handling. Patient-derived organoids provide expandable systems for studying genotype-linked copper phenotypes. We compare WD organoids, organoids from related copper disorders and supporting cellular models by cellular identity and measured function. We distinguish cell survival, intracellular copper burden, ATP7B localisation, ceruloplasmin copper loading and directional biliary export as complementary readouts. Two human copper-challenge studies tested ductal or progenitor-derived liver organoids under expansion conditions. Reported findings include acute copper sensitivity and, in one study, short-term survival rescue after correction of an ATP7B frameshift. Evidence from human WD organoids remains limited in donor and genotype representation. COMMD1-deficient canine organoids provide related-disease evidence for copper accumulation, gene supplementation and transplantation feasibility. Mouse intestinal enteroids and predominantly two-dimensional hepatocyte-like cells contribute tissue-specific ATP7B and variant-specific mechanistic evidence, respectively. Mature hepatocyte copper handling and directional apical export remain to be validated in human WD liver organoids. Emerging hepatocyte and multicellular platforms offer opportunities to examine polarity, compartment connectivity and cellular interactions relevant to copper handling. Priorities include verified cell identity, culture state and polarity, compartment-resolved copper measurements with mass balance, replication across independent donors and laboratories, and benchmarking against corresponding functional readouts in tissues or animal models. These steps would strengthen mechanistic studies and preclinical comparisons of selected interventions, with clinical predictive value requiring prospective validation against patient outcomes.
Juvenile acute respiratory distress syndrome (ARDS) remains a high-morbidity condition with no approved pharmacological therapy. Studies have shown that umbilical cord-derived mesenchymal stromal cells (UC-MSCs) represent a promising source of MSCs for treating ARDS in adult animals, with UC-MSC derived extracellular vesicles (UC-EVs) also demonstrating therapeutic promise given their immunomodulatory and anti-inflammatory potential. The present study investigates the therapeutic potential of using UC-EVs for treating juvenile ARDS. UC-EVs, isolated by ultracentrifugation, were used to treat lipopolysaccharide (LPS)-induced ARDS in juvenile (3–4 weeks of age) C57BL/6 mice via intravenous (IV) injection at three doses (200, 400, 800 µg/kg) 4 h following LPS administration; animals were sacrificed at 48 h to evaluate total protein in the bronchoalveolar lavage (BAL), innate immune cells in the lung and BAL, pro-inflammatory cytokines, surfactant protein-D (SP-D) and epithelial/endothelial barrier integrity. At an optimal dose of 800 µg/kg, IV administerd UC-EVs significantly improved epithelial-endothelial barrier function, reducing BAL protein and Evans Blue dye extravasation. Inflammation was attenuated with marked reductions in BAL IL-1β, TNF-α, and IL-6. UC-EVs also decreased immune cell infiltration and shifted macrophages toward an M2 phenotype, yielding a lower M1/M2 ratio in both lung tissue and BAL. In vitro analyses showed that UC-EVs diminished NLRP3 expression and IL-1β release in activated macrophages. Neutrophil infiltration and MPO expression in lung tissue were reduced, with Neutrophil extracellular trap (NET) formation also significantly decreased. UC-EVs protect against LPS-induced ARDS in juvenile mice by dampening lung inflammation and preserving epithelial-endothelial barrier function. Mechanistically, UC-EVs shift macrophage polarization, reduce NLRP3/IL-1β expression and decrease percentage of MPO/SYTOX-positive HL-60 cells.
Feline panleukopenia virus (FPV) is a highly contagious pathogen that can cause severe disease, particularly in young kittens. We developed a proof-of-concept antigen-delivery strategy using adipose-derived mesenchymal stem cells (ADSCs) engineered to express and secrete FPV VP2 protein. Lentiviral transduction achieved stable VP2 expression without measurably impairing ADSCs proliferation or migration under the conditions tested. In vivo imaging in mice showed that engineered ADSCs remained detectable at the injection site for approximately 21 days. In mice, ADSC-VP2 administration induced FPV-specific IgG, neutralizing antibody responses, lymphocyte proliferation, and cytokine changes. In five volunteer cats vaccinated on days 0, 21, and 42, FPV-specific antibody titers and PRNT50 activity remained detectable through 180 days. PBMC assays showed stimulation-index and cytokine responses after in vitro restimulation with VP2 or inactivated FPV, and immune sera qualitatively inhibited FPV-associated cytopathic changes in CRFK cells. Longitudinal complete blood counts and serum biochemical measurements showed no overt clinically relevant abnormalities during the 180-day observation period. These findings support ADSC-VP2 as a proof-of-concept cell-based antigen-delivery platform, protective efficacy remains to be established in controlled FPV challenge studies.